Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDeate Lung01 study of ifinatamab deruxtecan in previously treated extensive-stage small cell lung cancer
CTR20222027Phase 2Active
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ifinatamab deruxtecan in small cell lung cancer (SCLC), sponsored by Daiichi Sankyo Co., Ltd.. Started Oct 2022; status: active.
02
Drugs
ifinatamab deruxtecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20222027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222027.